AVGN7, a novel gene therapeutic for treating cancer cachexia
Ended Project Grant Awarded Last action
- Award ID
- R44CA221539
- Recipient
-
Aavogen Inc. UEI D7WBG8G7AWE4
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,002,000
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $134,809 | |
| Amendment | $0 | |
| Amendment | $1 | |
| Amendment | $0 | |
| Amendment | $660,235 | |
| Original award | $1,206,955 |
Quick answers
Who received award R44CA221539?
R44CA221539 was awarded to Aavogen Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2017.
How much is award R44CA221539 worth?
$2,002,000 has been obligated on R44CA221539.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award